0001628280-19-015081.txt : 20191213
0001628280-19-015081.hdr.sgml : 20191213
20191213161713
ACCESSION NUMBER: 0001628280-19-015081
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191213
FILED AS OF DATE: 20191213
DATE AS OF CHANGE: 20191213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Swirsky Douglas J
CENTRAL INDEX KEY: 0001375884
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31564
FILM NUMBER: 191284788
MAIL ADDRESS:
STREET 1: C/O REXAHN PHARMACEUTICALS, INC.
STREET 2: 15245 SHADY GROVE ROAD SUITE 455
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Fibrocell Science, Inc.
CENTRAL INDEX KEY: 0000357097
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870458888
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 405 EAGLEVIEW BOULEVARD
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 484-713-6000
MAIL ADDRESS:
STREET 1: 405 EAGLEVIEW BOULEVARD
CITY: EXTON
STATE: PA
ZIP: 19341
FORMER COMPANY:
FORMER CONFORMED NAME: ISOLAGEN INC
DATE OF NAME CHANGE: 20020320
FORMER COMPANY:
FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /DE
DATE OF NAME CHANGE: 19960330
FORMER COMPANY:
FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /CO
DATE OF NAME CHANGE: 19921008
4
1
wf-form4_157627181620899.xml
FORM 4
X0306
4
2019-12-13
1
0000357097
Fibrocell Science, Inc.
FCSC
0001375884
Swirsky Douglas J
C/O 405 EAGLEVIEW BLVD.
EXTON
PA
19341
1
0
0
0
Option to Purchase Common Stock
56.25
2019-12-13
4
D
0
534
D
2023-03-04
Common Stock
534.0
0
D
Option to Purchase Common Stock
82.35
2019-12-13
4
D
0
1600
D
2023-07-19
Common Stock
1600.0
0
D
Options to purchase common stock
62.1
2019-12-13
4
D
0
1200
D
2024-06-20
Common Stock
1200.0
0
D
Option to Purchase Common Stock
81.6
2019-12-13
4
D
0
2400
D
2025-06-24
Common Stock
2400.0
0
D
Option to Purchase Common Stock
14.25
2019-12-13
4
D
0
2400
D
2026-06-22
Common Stock
2400.0
0
D
Option to Purchase Common Stock
16.55
2019-12-13
4
D
0
6000
D
2027-06-22
Common Stock
6000.0
0
D
Option to Purchase Common Stock
2.36
2019-12-13
4
D
0
6000
D
2028-06-19
Common Stock
6000.0
0
D
Option to Purchase Common Stock
1.94
2019-12-13
4
D
0
12000
D
2029-06-12
Common Stock
12000.0
0
D
Pursuant to the Agreement and Plan of Merger, dated as of September 12, 2019 (the "Merger Agreement"), among Fibrocell Science, Inc. (the "Company"), Castle Creek Pharmaceutical Holdings, Inc. and Castle Creek Merger Corp., effective as of immediately prior to the effective time of the merger of the Company and Merger Sub, these shares of Company common stock were converted into the right to receive a cash payment equal to the per share merger consideration of $3.00.
/s/ Douglas J. Swirsky
2019-12-13